Orphanet: Efficacy and Safety of Velcade Plus Dexamethasone VD, VD Cyclophosphamide or VD Plus Lenalidomide in MMY Multiple Myeloma Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD Phase II coordination
x

Search for a networks

* (*) mandatory field

Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY (Multiple Myeloma) Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD (Phase II) (coordination)

  • Type of network : Multinational clinical trials
  • Geographic coverage : European
  • Funding body(ies) : -
  • Sponsor : Janssen-cilag international n.v.
  • Website
Last update: March 2011

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.